Delving into the Latest Updates on Diphenhydramine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Diphenhydramine hydrochloride (JP17/USP), Diphenhydramine Hydrochloride Softgels, Diphenhydramine Hydrochloroide

+ [13]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Common ColdPruritusRhinitis, Allergic+ [4]

Inactive Indication

Depressive Disorder, MajorMotion SicknessNasal Obstruction+ [2]

Originator Organization

Johnson & Johnson

Active Organization

Kowa Co., Ltd.Grand Pharmaceutical Group

Tianjin Jinyao Pharmaceutical Co., Ltd.

+ [2]

Inactive Organization

McNeil Consumer HealthcareJanssen-Cilag International NV

Bayer AG

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (04 Mar 1946),

HypersensitivityMotion SicknessParkinson Disease

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H22ClNO

InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N

CAS Registry147-24-0

The goal of this clinical trial is to evaluate the efficacy and safety of H1 receptor antagonist (diphenhydramine) combined with toripalimab plus standard platinum-based chemotherapy in the perioperative setting in subjects with operable NSCLC.
The subjects of this study are patients with histologically or cytologically confirmed stage IIIA-IIIB NSCLC (AJCC Version 9) who are planned to receive neoadjuvant therapy with toripalimab combined with standard platinum-based chemotherapy. Eligible subjects were randomized at a 1:1 ratio to receive 3-4 cycles of neoadjuvant diphenhydramine (an H1 receptor antagonist) plus toripalimab and standard platinum-based chemotherapy, or toripalimab plus platinum-based chemotherapy alone, followed by treatment response evaluation and definitive surgery. After surgery, the experimental group will receive maintenance therapy with diphenhydramine (an H1 receptor antagonist) plus toripalimab for 13-14 cycles, while the control group will receive toripalimab monotherapy for the same 13-14 cycles.

Start Date30 Jan 2026

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

CTRI/2025/12/098925

/ Not yet recruitingPhase 3

A Multicentric, Prospective, Parallel Group, Randomized, Active Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Diphenhydramine + Phenylephrine Syrup in Comparison with Fixed Dose Combination of Chlorpheniramine + Phenylephrine Syrup for the Symptomatic Treatment of Cough and Cold. - NIL

Start Date22 Dec 2025

Sponsor / Collaborator

Zydus Healthcare Ltd.

[+1]

NCT07285031

/ RecruitingNot ApplicableIIT

The Role of Histamines on Central Hemodynamics

When we exercise, more blood flow goes to our muscles, challenging our blood vessels. Following exercise, blood flow remains elevated and seems to be the reason for many of the positive cardiovascular benefits that occur with exercise. When the actions of histamine, a molecule primarily known for its role in allergies, are blocked, there is an attenuated blood flow response following exercise. However, this effect has never been studied in the blood vessels that supply our lungs. The purpose of this study is to examine the effects of histamines on pulmonary hemodynamics following exercise.

Start Date01 Dec 2025

Sponsor / Collaborator

University of British Columbia

100 Clinical Results associated with Diphenhydramine Hydrochloride

Login to view more data

100 Translational Medicine associated with Diphenhydramine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Diphenhydramine Hydrochloride

Login to view more data

4,136

Literatures (Medical) associated with Diphenhydramine Hydrochloride

01 Feb 2026·Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

The impact of Verapamil for radial access in diagnostic cerebrovascular angiograms: A retrospective case-control study

Article

Author: Burkhardt, Jan-Karl ; Jankowitz, Brian T. ; Ng, Jinggang Jenny ; Corral Tarbay, Antonio ; Sioutas, Georgios S. ; Romeo, Dominic ; Salem, Mohamed M. ; Aboutaleb, Pakinam E. ; Srinivasan, Visish M. ; Pukenas, Bryan

Introduction:

Different combinations of medications are utilized during wrist access for radial artery (RA) or ulnar artery (UA) catheterization in neuroendovascular procedures to preclude vasospasm. These “cocktails” commonly include the calcium channel blocker Verapamil, without established benefit. We analyze outcomes in patients with and without Verapamil in their “cocktail” by using a case-control cohort of our single-center experience.

Methods:

A prospective log of consecutive patients who underwent diagnostic cerebral angiograms using RA/UA access was retrospectively reviewed, and patients were grouped into Verapamil and non-Verapamil cohorts. The primary outcomes assessed were the presence of forearm skin rashes (hives) and RA/UA spasms. Our initial management included Verapamil (5 mg) in the cocktail, but Verapamil was removed after we noticed the development of hives in multiple patients immediately following its injection.

Results:

A total of 221 patients underwent 241 RA/UA diagnostic cerebral angiograms and were included in our analysis. One hundred and forty-nine patients (61.8%) underwent catheterization with Verapamil and 92 (38.2%) were catheterized without it. Four of the 149 patients in the Verapamil group (2.7%) developed hives during the procedure and were treated with Benadryl (25 mg). Of the 92 patients who did not receive Verapamil, there were zero (0%) cases of hives and one (1.1%) case of vasospasm.

Conclusion:

Verapamil in the “cocktail” for wrist access diagnostic cerebral angiograms was associated with periprocedural hives, but not associated with a significant reduction in spasm compared to the non-Verapamil group. Our findings suggest that the administration of prophylactic Verapamil for these procedures may not be necessary.

01 Dec 2025·Alzheimers & Dementia

Medication Administration Practices and Chemical Restraint Use by Dementia Family Caregivers

Article

Author: Browning, Wesley R ; Winstead, Vicki ; Pickering, Carolyn

Abstract:

Background:

The presentation explores the practices of medication administration and the potential use of chemical restraints by family caregivers of individuals with dementia. Chemical restraint is defined as any drug used for discipline or convenience rather than to treat a person’s medical symptoms. The prevalence of chemical restraints in nursing homes has decreased due to CMS programs, but caregivers play a critical role in managing medications for persons with Alzheimer's disease and related dementias (ADRD) .

Methods:

This paper reviews preliminary data from 85 family caregiving dyads and over 2,012 daily observations. Complete medication lists were gathered at enrollment, and caregivers completed 31 days of daily surveys reporting on behavioral symptoms and the pharmacological and non‐pharmacological strategies used to manage these symptoms. The frequency of PRN medication usage, types of medications administered and potential chemical restraint were determined.

Results:

The findings indicate that 42% of caregivers administered a “PRN” medication over 31 days, with PRN medications given on 18% of days. Safety‐related behavioral symptoms were reported on 9% of days, and PRN medications were given on 45% of those days. Non‐safety‐related behavioral symptoms were reported on 70% of days, with PRN medications given on 14% of those days. Importantly, about half of medications given as “PRN” by caregivers were not prescribed as such but included additional dosages of scheduled medications, over‐the‐counters (i.e., Benadryl), CBD/THC and drug divergence. We estimate approximately 15% of caregivers were using chemical restraints, and 16% were using potentially inappropriate medication practices.

Conclusions:

These findings underscore the urgent need to address informal chemical restraint practices occurring in home settings, where oversight is limited and caregivers may lack adequate guidance. The use of non‐prescribed substances and potentially inappropriate medications to manage behavioral symptoms highlights significant gaps in caregiver support and education. Interventions that promote safe medication management such as deprescribing initiatives, tailored caregiver training, and programs to build non‐pharmacologic coping strategies are critically needed. Future work should prioritize the development of tools to identify chemical restraint in community settings and evaluate scalable strategies that empower caregivers while protecting the dignity and well‐being of persons living with dementia.

01 Nov 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Experimental characterization and QSAR modeling of maximum uptake and distribution factor for neutral and ionic micropollutants on granular activated carbon in artificial and real wastewaters

Author: Cho, Chul-Woong ; Park, Si-Hyeon ; Lee, Kwan-Yong ; Cho, Bo-Gyeon ; Jin, Se-Ra ; Cheon, Jeong-Min

Granular activated carbon (GAC)-based adsorption treatment for micropollutant removal is known to be cost-effective and environmentally sustainable.However, an efficient method is urgently needed to assess the applicability of GAC for a diverse range of micropollutants in various wastewater conditions.Therefore, we developed predictive models to determine the maximum uptake (qmax; calculated by the Langmuir model) and distribution factor (KF; calculated by the Freundlich model) of a range of micropollutants on GAC, which can help overcome exptl. limitations, save resources and time, and provide a deeper understanding of adsorption mechanisms.Exptl. isotherms for controlled conditions to obtain the qmax and KF were performed for both artificial and real wastewaters. qmax values of micropollutants were similar in both wastewaters, but KF values differed slightly.Exptl. obtained qmax and KF values were used in linear free energy relationship-based predictive modeling.The results showed reasonable predictive accuracy for qmax, with R2 values ranging from 0.844 to 0.875 and standard errors between 0.144 and 0.072 log units for both artificial and real wastewater conditions.For KF, the model showed R2 values between 0.803 and 0.762, with standard errors ranging from 0.189 to 0.163 log units.The two models showed high potential for use in GAC-based micropollutant removal.

44

News (Medical) associated with Diphenhydramine Hydrochloride

02 Mar 2026

·www.biospace.com

Avenacy Announces Launch of Diphenhydramine Hydrochloride Injection, USP in the U.S. Market

Represents the Company’s 26th product launch since inception in October 2023. SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States. The product Is the generic equivalent of BENADRYL ® , as approved by the U.S. Food and Drug Administration, and is indicated for the treatment of allergic reactions, including as an adjunct in anaphylaxis after acute symptoms have been controlled, for motion sickness, and for certain cases of parkinsonism when oral therapy is not feasible. Each vial of Diphenhydramine Hydrochloride Injection, USP contains 50 mg per 1 mL (50 mg per mL) and is available as a carton of 25 single-dose vials. “Since launching Avenacy in October 2023, we have remained focused on building a reliable portfolio of essential injectable medications that hospitals depend on every day to deliver consistent care to patients,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “The addition of Diphenhydramine Hydrochloride Injection marks our 26th product offering and our first launch of 2026. We look forward to continuing to strengthen our portfolio with critical injectable medicines.” In line with Avenacy’s mission to champion patient safety and streamline patient care, Diphenhydramine Hydrochloride Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Diphenhydramine Hydrochloride Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards. U.S. sales of Diphenhydramine Hydrochloride Injection, USP were approximately $17.2 million for the twelve months ending December 2025. 1 Indications: Diphenhydramine Hydrochloride Injection, USP is effective in adults and pediatric patients, for the following conditions when the oral form is impractical. Antihistaminic For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion Sickness For active treatment of motion sickness. Antiparkinsonism For use in parkinsonism, when oral therapy is impossible or contraindicated. Contraindications: Use in Neonates or Premature Infants Diphenhydramine Hydrochloride Injection, USP should not be used in neonates or premature infants. Use in Nursing Mothers Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Use as a Local Anesthetic Because of the risk of local necrosis, this drug should not be used as a local anesthetic. Antihistamines are also Contraindicated in the Following Conditions Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure. Please see link for Full Prescribing Information. BENADRYL ® is a registered trademark of Kenvue Inc. 1 Source: IQVIA About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit . Contacts Media Contact FTI Consulting Avenacy@fticonsulting.com

Drug ApprovalBiosimilar

04 Nov 2025

·www.pharmaceutical-technology.com

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

The FDA updated the label for Tylenol in September 2025 amid pressure from the Trump administration. Credit: Kenishirotie via Shutterstock.com. Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s largest consumer health companies, Kimberly-Clark said it would acquire all of Kenvue’s common stock, creating a conglomerate that will generate annual revenue of $32bn. According to the deal, shareholders in Kenvue – a company that J&J siphoned off in 2023 – will receive $3.50 per share, as well as 0.14625 of Kimberly-Clark shares for each Kenvue share held at closing. The total consideration to Kenvue investors is $21.01 per share. The transaction, which is expected to close in the second half of 2026, will see Kimberly-Clark shareholders own around 54% of the combined company while Kenvue shareholders will own the remaining 46%. The deal is one of the largest in the consumer sector for several years and adds to a strong mergers and acquisition (M&A) pickup across the pharmaceutical industry in 2025. However, the deal is not without its points of contention. Kenvue’s top-selling product is Tylenol (acetaminophen), the common over-the-counter (OTC) pain medication that has been under scrutiny by the US Government over safety concerns. US President Donald Trump has made claims that the medicine, known as paracetamol in most other countries, has been linked to autism when used during pregnancy. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The US Food and Drug Administration (FDA) updated the label for Tylenol in September 2025, with a warning added for pregnant women that the drug can “increase the risk of neurological conditions such as autism and ADHD in children”. Kenvue has since filed a petition to the FDA rebuking the claims. As well as Tylenol, Kenvue is known for making Band-Aid, antihistamines Zyrtec (cetirizine) and Benadryl (budesonide), and skincare brands Neutrogena and Aveeno. Kimberly-Clark is therefore looking beyond Tylenol, stating that the transaction “brings together two iconic American companies to create a portfolio of complementary products”. When asked about the Tylenol controversy during a conference call, Kimberly-Clark’s CEO Mike Hsu said: “We reviewed this transaction in the same way that we run the business, with incredible rigor, thoughtfulness and discipline. The board carefully considered all the risks and all the opportunities. We had multiple sessions with the board with the world’s foremost scientific, medical, regulatory and legal experts. “It was definitely not opportunistic, definitely strategic.” Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

AcquisitionDrug Approval

17 Oct 2025

·www.drugs.com

U.S. Drug Supply Deeply Dependent on Chinese Ingredients

FRIDAY, Oct. 17, 2025 — A new analysis reveals how deeply the U.S. drug supply chain depends on China, and experts warn that a trade war could leave American patients at risk. Nearly 700 medicines used in the U.S. contain at least one chemical sourced only in China, according to U.S. Pharmacopeia , a nonprofit that monitors the drug supply. Those chemicals are crucial ingredients in drugs that treat common conditions, including heart disease , cancer and HIV . The findings were published Wednesday as tensions between Washington and Beijing continue to grow. "Our hope is that by having better data and more visibility, that can inform targeted interventions into creating resilience and security for patients,” Carrie Harney , an official at U.S. Pharmacopeia, told The New York Times . China is the only known source of certain ingredients in antibiotics like amoxicillin , as well as generic drugs for seizures, allergies and heart problems. Even the chemical ingredients in Benadryl , the popular allergy medication, come from China. While factories in India, Canada and other countries handle the later stages of production, China dominates the main steps. Manufacturing these raw materials is considered unprofitable in the U.S. due to higher labor costs and strict environmental rules, while Chinese facilities can produce them at a lower cost, The Times reported. President Donald Trump recently proposed a 100% tariff on all products from China, a move that could drive up the cost of medicines that rely on Chinese ingredients. The administration has said generic drugs won’t face tariffs, but many brand-name pharmaceutical companies are rushing to build or expand domestic plants in response to ongoing pressure to bring manufacturing back to the U.S. However, experts warn that these new plants won’t solve the core problem. Most are designed to handle later stages of drug production, not the raw chemicals currently coming from overseas. The multistep process of making medicine often spans several countries: raw materials from China, active ingredients from India and final formulations from other places. That means even drugs that seem globally sourced can still rely on China. For example, while factories in Jordan, India and Canada make finished amoxicillin, two of its raw materials are made only in China, the report found. Sources The New York Times, Oct. 15, 2025

Biosimilar

100 Deals associated with Diphenhydramine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00669	Diphenhydramine Hydrochloride	D04AA32 R06AA02	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Common Cold	Japan	Kowa Co., Ltd.	20 Jul 1984
Pruritus	Japan	Kowa Co., Ltd.	20 Jul 1984
Rhinitis, Allergic	Japan	Kowa Co., Ltd.	20 Jul 1984
Rhinitis, Allergic, Seasonal	Japan	Kowa Co., Ltd.	20 Jul 1984
Rhinitis, Vasomotor	Japan	Kowa Co., Ltd.	20 Jul 1984
Urticaria	Japan	Kowa Co., Ltd.	20 Jul 1984
Hypersensitivity	United States	McNeil Consumer Healthcare	04 Mar 1946
Motion Sickness	United States	McNeil Consumer Healthcare	04 Mar 1946
Parkinson Disease	United States	McNeil Consumer Healthcare	04 Mar 1946

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	Phase 3	United States	Bayer AG	01 Oct 2010
Depressive Disorder, Major	Phase 1	Belgium	Janssen-Cilag International NV	11 Jun 2015
Depressive Disorder, Major	Phase 1	Germany	Janssen-Cilag International NV	11 Jun 2015
Depressive Disorder, Major	Phase 1	Netherlands	Janssen-Cilag International NV	11 Jun 2015
Nasal Obstruction	Phase 1	-	Johnson & Johnson Holdco (NA), Inc.	01 Oct 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05405166 (IRAKLIA, CTgov)	Phase 3	Recurrent Multiple Myeloma	531	isatuximab+pomalidomide+dexamethasone (Isa-IV + Pd)	xavivvkdns = mnkflkahmu suctvhlgwl (xbljikmjgi, xreopqectg - ywsxtlhaoq) View more	-	14 Nov 2025
				isatuximab+pomalidomide+dexamethasone (Isa-SC + Pd)	xavivvkdns = mqidfsiaxd suctvhlgwl (xbljikmjgi, uhkkqgcznl - falsvwgmxn) View more
NCT05676216 (Pubmed \| JAMA Netw Open)	Not Applicable	Vestibular Neuronitis	222	Diphenhydramine	fxbjdtfllz(ptzoswzngy) = cnvewkajhk uzwpjaiois (nhnelsgkfb, 2.7) View more	Positive	06 Nov 2025
				Sodium Bicarbonate	fxbjdtfllz(ptzoswzngy) = ayvbyxtqvw uzwpjaiois (nhnelsgkfb, 2.2) View more
NCT06019728 (SHORTEN, CTgov)	Phase 4	Fabry Disease	8	Fabrazyme	woyzuinote(ujqkavxnae) = naheiokvrk cmkzcbulxq (tvsgzpdiqr, uatpzjgjnn - cdzhynyqph) View more	-	21 Oct 2025
NCT03493945 (QuEST1, CTgov)	Phase 1/2	Locally Advanced Malignant Solid Neoplasm \| Advanced Malignant Solid Neoplasm	59	castration+M7824+BN-Brachyury (Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A)	hdwhcmydwc = iajxummlip takstnvkdh (mdbnncbmnf, houcqrffoz - ktsdallyqp) View more	-	08 Jun 2025
				N-803+M7824+BN-Brachyury (All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion)	hdwhcmydwc = ytziqhqqjo takstnvkdh (mdbnncbmnf, qiemfqblyq - biyaoxskvw) View more
NCT02356159 (CTgov)	Phase 1/2	Hodgkin's Lymphoma \| Multiple Myeloma \| acute leukemia ... View more	34	Epinephrine+PET+Acetaminophen+Prednisone+Palifermin+Diphenhydramine+Rituximab (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose)	bxgilpyozp = crgevxidbm ooosqvqmtk (yrzuzyirjo, hnxetyvydu - xqpfxuaakl)	-	05 Jun 2025
				Epinephrine+PET+Acetaminophen+Prednisone+Palifermin+Diphenhydramine+Rituximab (1/Phase 1: Dose Escalation Arm - Palifermin)	ynvyqxbedk = evsmncdmgu ssokkpcyxz (pfsjliwefy, kgfyagmmhj - qukftqrguz)
NCT03107182 (OPTIMA II \| OPTIMA-II, CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| HPV positive oropharyngeal squamous cell carcinoma \| Human Papillomavirus-Related Squamous Cell Carcinoma ... View more	72	Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA))	irkgrrhppf = jlborbxnmj gjvjsntaxg (zvezrxiznv, juqobiavxf - kyklybsmsn) View more	-	06 May 2025
				Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA))	irkgrrhppf = etprisvnao gjvjsntaxg (zvezrxiznv, dtgdplunfy - yyfvrbgzpk) View more
NCT05586477 (Pubmed \| Med Sci Sports Exerc)	Phase 4	Heat Stress Disorders	20	Diphenhydramine 50 mg	lomvfudeni(uokzbieecw) = wxlmqhumou fnwtphunis (omrnjezglf ) View more	Positive	01 Dec 2024
				Placebo	lomvfudeni(uokzbieecw) = tibvcdzzkj fnwtphunis (omrnjezglf ) View more
NCT03185130 (I-FiBH, CTgov)	Phase 4	Headache	58	Normal Saline 5mL+Prochlorperazine+Diphenhydramine (Standard Treatment Arm)	xdqdcfmixf(wpgwscnzxm) = caqqyjekkh qnnbztrcpp (mpjssrpych, 29.3) View more	-	06 Jun 2024
				Normal Saline 20mL/kg+Prochlorperazine+Diphenhydramine (Study Arm)	xdqdcfmixf(wpgwscnzxm) = wmjwroohjq qnnbztrcpp (mpjssrpych, 31.0) View more
NCT01059786 (CTgov)	Phase 2	Hairy Cell Leukemia	69	Epinephrine+Saline+Bronchodilators+Acetaminophen+bendamustine+Pentostatin+Diphenhydramine+Rituximab	uftzqtxghu = pceqekqthn rbfgawvblx (szbiwcbtmy, npwgvbgjoj - iiqggerric) View more	-	01 May 2024
NCT03258593 (MP16-20, CTgov)	Phase 1	Non-Muscle Invasive Bladder Neoplasms	15	Urine cytology+Acetaminophen+Vicineum+Durvalumab+Antihistamine (Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg)	aottwpgydw = blbrbyydkm gmkqbmsjqs (tlfwfcbnwv, iytpghpuvb - kwnkivpsyj) View more	-	26 Oct 2023
				Urine cytology+Acetaminophen+Vicineum+Durvalumab+Antihistamine (Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg)	aottwpgydw = cpjzkwqxmn gmkqbmsjqs (tlfwfcbnwv, mxasjjnyvi - xrylxgsjnn) View more